List of Excipients in Branded Drug SYMBYAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3230	DIMETHICONE
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3230	FERRIC OXIDE RED
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3230	FERRIC OXIDE YELLOW
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3230	GELATIN
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3230	SODIUM LAURYL SULFATE

Last updated: August 10, 2026

SYMBYAX is a fixed-dose capsule combining olanzapine and fluoxetine hydrochloride. Its excipient strategy is conventional and cost-efficient: hard gelatin capsules, lactose-based powder filling, pregelatinized starch, magnesium stearate, sodium lauryl sulfate, talc, titanium dioxide, and permitted colorants. The commercial opportunity is concentrated in generic and reformulated versions that improve dose flexibility, swallowing, stability, or manufacturing efficiency rather than in proprietary excipient differentiation.

SYMBYAX Excipient Strategy and Commercial Opportunities

What is SYMBYAX and how does its formulation work?

SYMBYAX contains olanzapine, an atypical antipsychotic, and fluoxetine hydrochloride, a selective serotonin reuptake inhibitor. The product is approved for depressive episodes associated with bipolar I disorder and for treatment-resistant depression in adults. Eli Lilly markets SYMBYAX in four capsule strengths:

SYMBYAX strength	Olanzapine	Fluoxetine hydrochloride	Dosage form
3 mg/25 mg	3 mg	25 mg	Hard capsule
6 mg/25 mg	6 mg	25 mg	Hard capsule
6 mg/50 mg	6 mg	50 mg	Hard capsule
12 mg/25 mg	12 mg	25 mg	Hard capsule
12 mg/50 mg	12 mg	50 mg	Hard capsule

The product uses a powder-filled hard capsule rather than a tablet or modified-release delivery system. The formulation does not depend on a complex drug-delivery platform. Its principal technical challenges are low-dose olanzapine uniformity, powder flow, segregation control, moisture management, capsule-fill consistency, and long-term stability.

The FDA label identifies the inactive ingredients as gelatin, lactose monohydrate, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, talc, titanium dioxide, and colorants. Capsule-color components vary by strength. [1]

What excipients are used in SYMBYAX capsules?

The excipients perform standard but commercially important functions.

Excipient	Primary function	Formulation relevance
Lactose monohydrate	Diluent and bulking agent	Provides fill volume for low-dose olanzapine and supports powder handling
Pregelatinized starch	Binder, disintegrant, and flow aid	Supports capsule-plug integrity and dispersion after administration
Magnesium stearate	Lubricant	Reduces friction during blending and capsule filling
Sodium lauryl sulfate	Wetting agent and surfactant	Supports wetting of hydrophobic drug particles and may improve dispersion
Talc	Glidant and anti-adherent	Improves powder movement and reduces equipment sticking
Gelatin	Capsule shell	Enables immediate-release oral delivery
Titanium dioxide	Opacifier and pigment	Controls capsule appearance and light transmission
Permitted colorants	Product identification	Differentiates dose strengths and supports brand recognition

The formulation uses a familiar excipient platform that is widely available from pharmaceutical-grade suppliers. That limits supply-chain differentiation but lowers manufacturing barriers for generic developers.

Why is lactose strategically important in SYMBYAX?

Lactose is the principal volume-building excipient in a formulation containing only 3 mg to 12 mg of olanzapine. Without a diluent, the active ingredients would not occupy enough volume for reliable capsule filling and content uniformity.

Lactose also creates formulation-development considerations. Both olanzapine and fluoxetine hydrochloride contain functional groups that can interact with reactive impurities or moisture under stressed conditions. A generic manufacturer must control lactose grade, water activity, particle-size distribution, and storage conditions. The relevant commercial opportunity is not simply lactose supply. It is supply of tightly controlled direct-blend lactose with documentation supporting:

• Particle-size consistency
• Low bioburden
• Controlled moisture
• Good flowability
• Low variability between lots
• Compatibility with low-dose blend uniformity requirements

Spray-dried lactose or engineered co-processed diluents could support improved flow and reduced segregation. Such materials would need to demonstrate equivalent or superior performance without creating a formulation difference that complicates an ANDA.

How does the excipient system address low-dose content uniformity?

Olanzapine represents a small fraction of total powder mass, particularly in the 3 mg/25 mg strength. The formulation therefore requires a validated blending strategy.

Key controls include:

1. Particle-size matching between active ingredients and excipients.
2. Geometric dilution of olanzapine into a portion of the diluent.
3. Controlled blending time to avoid overmixing and segregation.
4. Use of pregelatinized starch and talc to support flow.
5. Lubrication at a controlled magnesium stearate concentration.
6. In-process capsule-weight and blend-uniformity testing.
7. Validation of hopper residence time and line clearance.

A generic product with better blend uniformity at commercial scale could reduce batch rejection and improve manufacturing economics. This is a practical opportunity for contract development and manufacturing organizations with expertise in low-dose oral solids.

What formulation patents protect SYMBYAX?

SYMBYAX is a small-molecule fixed-dose combination, not a biologic. Its historical patent estate centered on the olanzapine and fluoxetine combination, related therapeutic use, and the underlying active ingredients. The product is no longer protected by the type of broad market exclusivity associated with a newly approved branded combination.

The key patent categories were:

Patent category	Strategic purpose	Current commercial significance
Olanzapine compound patents	Protect the antipsychotic active ingredient	Expired
Fluoxetine compound patents	Protect the antidepressant active ingredient	Expired
Combination patents	Cover coadministration or fixed-dose use	Historical relevance; expiry has enabled generic competition
Method-of-use patents	Cover bipolar depression or treatment-resistant depression	May affect labeling and litigation history, but do not generally block all non-infringing generic sales after expiry
Formulation patents	Protect capsule composition or delivery characteristics	No known complex delivery platform remains central to the product
Pediatric exclusivity	Temporarily extends certain listed protections	Expired

The FDA Orange Book, rather than the commercial label alone, is the controlling source for current listed patents and exclusivity. [2] Current strategic analysis should distinguish between patents covering the active ingredients, patents covering the combination, and patents that may have expired but remain relevant to historical Paragraph IV litigation.

When did SYMBYAX lose exclusivity?

SYMBYAX received FDA approval in 2003. Its major commercial protections have expired, and generic olanzapine/fluoxetine products have entered the U.S. market through the abbreviated new drug application pathway. The product does not have biologic exclusivity, and biosimilar competition is not applicable.

Milestone	Date or status
FDA approval of SYMBYAX	2003
Primary small-molecule patent barriers	Expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	Expired
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Current market structure	Branded product plus generic competition

The precise first generic launch date depends on the product, applicant, and market channel. FDA approval records and the Orange Book provide the relevant product-level status. [2,3]

Which companies are challenging SYMBYAX through generic filings?

Generic competition is based on ANDAs for olanzapine and fluoxetine capsules. Generic manufacturers compete on the same active ingredients, strengths, route of administration, and dosage form. The main commercial barriers are bioequivalence, blend uniformity, stability, manufacturing scale, and pharmacy-channel economics.

Paragraph IV certifications may have been used against historical listed patents. A Paragraph IV filing alleges that a listed patent is invalid, unenforceable, or not infringed. It can trigger patent litigation and, in certain circumstances, a 30-month stay of FDA approval. Those procedural protections are time-limited and do not create continuing market exclusivity after the underlying patents expire. [4]

The relevant competitive set includes:

• Authorized or branded SYMBYAX supply
• Generic olanzapine/fluoxetine capsules
• Separate olanzapine and fluoxetine prescriptions
• Other branded or generic treatments for bipolar depression
• Other antidepressant-antipsychotic combinations

Separate prescriptions are an important substitute. A patient can receive olanzapine and fluoxetine as two products, although the fixed-dose capsule offers prescription simplicity and may reduce dispensing complexity.

What commercial opportunities exist for SYMBYAX excipients?

The strongest opportunities are upstream and formulation-oriented.

Pharmaceutical-grade diluents

Suppliers can offer lactose and alternative diluents optimized for low-dose powder blends. Products with consistent particle size, low moisture, and improved flow may reduce process variability.

Co-processed excipients

Co-processed lactose-starch or microcrystalline cellulose-starch systems could support better flow and capsule-fill performance. The value proposition is manufacturing efficiency, not patent protection around SYMBYAX itself.

Surfactant and wetting systems

Sodium lauryl sulfate is present at a low level and performs a functional role. Suppliers could compete with alternative wetting agents, but any substitution would require formulation bridging, dissolution comparison, stability data, and regulatory justification.

Capsule-shell supply

Hard gelatin capsules remain a stable supply opportunity. Manufacturers can compete through color consistency, dimensional control, defect reduction, and supply reliability. Hypromellose shells could support vegetarian positioning or reduce gelatin-related procurement concerns, but the change would require comparative development and regulatory assessment.

Stability-enhancing excipients

Low-moisture excipients, oxygen-control packaging, and improved barrier materials may support longer shelf life or more robust distribution. These options are more likely to create value in contract manufacturing and private-label supply than in a new branded SYMBYAX patent strategy.

Reformulated dosage forms

Potential product concepts include:

• Sprinkle capsules
• Orally disintegrating tablets
• Smaller capsules
• Flexible-dose combination packs
• Unit-dose packaging
• Alternative capsule shells
• Modified dosing configurations using separate strengths

These products could support lifecycle management, but a new dosage form would not automatically receive the market position of the original product. FDA approval would depend on the regulatory pathway and the degree of formulation and clinical change.

What FDA regulatory pathway applies to a SYMBYAX generic?

A conventional generic capsule would normally use the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The formulation may use different inactive ingredients if the product remains acceptable for safety, performance, and regulatory purposes. [3,5]

A substantially reformulated product may require a 505(b)(2) application. That pathway can support a new dosage form, delivery system, or formulation that relies partly on FDA findings for an approved product while requiring additional data for the modification.

The regulatory distinction is commercially important:

Product strategy	Likely pathway	Main opportunity
Same capsule, same strengths	ANDA	Low-cost generic supply
Alternative excipients in same dosage form	ANDA, subject to acceptability	Manufacturing or patient-use improvement
Orally disintegrating formulation	Potentially 505(b)(2)	Swallowing and adherence differentiation
Sprinkle formulation	Potentially 505(b)(2) or other pathway	Administration flexibility
New dosing regimen	505(b)(2) or supplemental strategy	Clinical and commercial differentiation
New combination packaging	Depends on product design	Adherence and dispensing convenience

How strong is the SYMBYAX patent estate?

The current patent estate is commercially weak compared with an active branded product protected by unexpired composition, formulation, and method-of-use patents. The principal value now lies in the approved reference product, established clinical identity, manufacturing know-how, and prescriber familiarity.

The remaining risks for a generic or reformulator are primarily regulatory and operational:

• Failure to demonstrate blend uniformity
• Dissolution differences caused by excipient substitution
• Stability failures involving moisture or oxidation
• Capsule-shell incompatibility
• Labeling differences
• Bioequivalence failure
• Manufacturing-scale segregation
• Patent claims covering a specific method of use or formulation, if any remain listed

A generic developer should treat the Orange Book as the operative patent source and review FDA litigation records before launch. [2,4]

What generic launch scenarios exist for SYMBYAX?

Three launch scenarios are commercially relevant.

Low-cost multisource generic

This is the most likely market model. The product uses standard excipients and existing capsule-filling equipment. Pricing pressure is high, and scale, wholesaler access, and manufacturing cost determine profitability.

Differentiated generic

A manufacturer could offer improved packaging, capsule colors, supply reliability, or a more robust excipient system. Differentiation would be modest because the active ingredients and dosage form are established.

Reformulated product

A 505(b)(2) product could target swallowing difficulty, administration convenience, or improved dosing flexibility. This strategy requires more development and regulatory investment but may avoid direct price competition with standard capsules.

What revenue exposure and licensing opportunities exist?

SYMBYAX-specific revenue is not generally reported as a standalone line item in public corporate filings. Commercial exposure is therefore best assessed through market share, generic price erosion, prescription volume, and the value of the olanzapine and fluoxetine components rather than through a separately disclosed branded revenue figure. [6]

Licensing opportunities are more likely in:

• Co-processed excipients
• Capsule shells
• Direct-blend manufacturing systems
• Contract manufacturing
• Private-label generic supply
• Formulation platforms for orally disintegrating or sprinkle products
• Regional distribution and commercialization rights

An excipient supplier seeking a product-specific license would face limited leverage if its ingredient is nonexclusive and pharmacopeial. Stronger negotiating leverage would require a documented manufacturing advantage, a protected co-processed composition, or a formulation platform that materially improves performance.

How does SYMBYAX compare with separate olanzapine and fluoxetine products?

Factor	SYMBYAX	Separate olanzapine plus fluoxetine
Administration	One capsule	Two products
Dose flexibility	Limited to marketed fixed strengths	Broad independent titration
Manufacturing	Combination blend and capsule filling	Separate established products
Generic competition	Combination ANDAs	Competition for each component
Adherence	Potential convenience advantage	More complex regimen
Formulation opportunity	Fixed-dose reformulation	Greater dosing flexibility
Patent risk	Combination and use claims	Component-specific and use claims

The fixed-dose product has convenience value, but separate products provide clinicians with greater control over olanzapine and fluoxetine dosing. That tradeoff limits the pricing power of a branded or reformulated combination.

Key Takeaways

• SYMBYAX is an immediate-release hard capsule containing olanzapine and fluoxetine hydrochloride.
• Its excipient system is conventional and includes lactose monohydrate, pregelatinized starch, magnesium stearate, sodium lauryl sulfate, talc, gelatin, titanium dioxide, and colorants.
• The main technical issue is low-dose olanzapine uniformity within a powder-filled capsule.
• Generic competition is established through the ANDA pathway; biosimilar competition does not apply.
• The historical patent estate has expired or lost most of its blocking commercial effect.
• The strongest excipient opportunities involve engineered diluents, co-processed systems, capsule shells, stability control, and contract manufacturing.
• A differentiated reformulation would likely require a more substantial regulatory pathway than a conventional ANDA.
• Commercial returns are likely to be stronger in generic manufacturing and excipient supply than in a new standalone branded SYMBYAX strategy.

FAQs About SYMBYAX Excipients and Commercial Strategy

Can lactose-free SYMBYAX be developed?

A lactose-free formulation is technically possible, but it would require replacement of the diluent system and comparative data on blend uniformity, dissolution, stability, and bioequivalence.

Is SYMBYAX suitable for an orally disintegrating tablet?

The active ingredients can support an orally disintegrating formulation, but the product would require new development around taste masking, mechanical strength, disintegration time, moisture protection, and regulatory strategy.

Does SYMBYAX have biosimilar risk?

No. SYMBYAX contains small-molecule active ingredients and competes through generic, not biosimilar, pathways.

Can a manufacturer change the SYMBYAX capsule shell?

A generic manufacturer may use an alternative capsule-shell composition if the product meets applicable quality, performance, safety, and regulatory requirements. A shell change can affect moisture transfer, dissolution, appearance, and stability.

Is there a strong licensing case for a SYMBYAX-specific excipient?

Usually not for a standard excipient. A stronger licensing case would require a proprietary co-processed excipient, validated manufacturing advantage, or reformulated product with a distinct regulatory and commercial position.

References

1. U.S. Food and Drug Administration. (2023). SYMBYAX (olanzapine and fluoxetine hydrochloride) prescribing information. Eli Lilly and Company.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2025). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024). Paragraph IV drug product applications: Patent certifications and litigation information. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly soluble, highly permeable drug products. U.S. Department of Health and Human Services.

6. Eli Lilly and Company. (2024). Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.